Objectives Clinical long-term outcomes of women with uterine leiomyosarcoma (ULMS) with different types of hysterectomy (open abdominal, vaginal, laparoscopic and switch from laparoscopic to open abdominal) were compared according to morcellation and other factors. Materials The clinical cancer registry Regensburg (Germany) registered 64 patients between 2004 and 2013 with ULMS. A retrospective cohort analysis was performed using the Kaplan-Meier method to estimate 5-year overall survival (OAS), recurrence-free survival (RFS) and recurrence rates. To compare surgery with or without morcellation log rank test was used. To adjust for age, FIGO stage, grading and other factors multivariable Cox regression models were applied to estimate hazard ratios (HR). Results In the cohort of 64 patients 15 underwent morcellation, preferably during laparoscopic surgery. Although numbers were small we performed analysis for OAS and RFS. Median OAS for morcellation was 10.6 vs. 6.4 years for non morcellation. 5y-OAS was 76.0 % for morcellation compared to 54.8 % in patients without morcellation (p = 0.115). Cox regression models rendered an unadjusted (univariable) HR 0.428 for morcellation vs. nonmorcellation (p = 0.125) and an adjusted (multivariable) HR 0.644 (p = 0.406). 5y-RFR was 64.0 % compared to 42.8 % in patients without morcellation (p = 0.104; unadjusted HR 0.484, p = 0.111; adjusted HR 0.607, p = 0.306). Conclusion In general, the prognosis of patients with ULMS is poor. In our cohort, women who underwent hysterectomy with morcellation had a better cumulative OAS and RFS than women without morcellation. Although we adjusted for differences between women with and without morcellation regarding age, grading and stage, there were no statistically significant differences between the groups.
Introduction
Uterine leiomyosarcoma (ULMS) is a highly malignant, rapidly growing and a rare mesenchymal tumor which makes up to 1-2 % of uterine malignancies [1] . The annual incidence of ULMS is 0.64 per 100,000 women per year [2] . Treatment options include surgery, chemotherapy, hormone therapy, targeted therapy and radiotherapy or their combinations [3] . However, surgery is the most important treatment procedure [4] . In general, ULMS patients are asymptomatic, or its symptoms resemble those of a (benign) leiomyoma. At present there are no reliable radiological techniques available to differentiate ULMS from leiomyoma. This is why most patients with early stage ULMS are initially treated for myoma [5, 6] . Thus, a malignancy is often diagnosed postoperatively. Benefits and gaining popularity of laparoscopic over open abdominal surgical techniques also increase the use of tissue morcellation. Although only few studies on the safety of morcellation in ULMS exist, there is evidence for the risk of disadvantageous inadvertently tumor tissue spreading [7, 8] . This study was performed to compare clinical outcomes of morcellation in patients with ULMS analysing data from a population based clinical cancer registry.
Materials and methods
First, a retrospective unicenter analysis was performed at the University Department of Gynecology and Obstetrics Regensburg (Bavaria, Germany) to verify incidental ULMS rate between 2008 to 2013 in patients with myoma resections. Using OPS codes version 2015 and ICD10 codes, patient data was scanned for the following keywords: laparoscopic supracervical hysterectomy (LASH) OPS code 5-682, hysterectomy (HE) OPS code 5-683 and myoma enucleation OPS code 5-681.8 and 0.9, diagnosis fibroid ICD10-D25 and malignancy of corpus uteri ICD10-C54.
Second, data from the Tumor Center Regensburg (Bavaria, Germany) were analysed. The database of this clinical cancer registry covers a population of more than 2.2 million people including the University Hospital Regensburg, 53 regional hospitals and more than 1500 practicing doctors. For this investigation 16 gynecological departments contributed surgery reports from patients with ULMS, which also included the collected data from the retrospective unicenter analysis mentioned above. Documentation included diagnosis, treatment, long term follow-up, course of disease, and mortality. Vital status was additionally obtained from regional registry offices and death certificates with end of follow-up in December 2014. Pathological records were reviewed for the current version (2009) of the International Federation of Obstetrics and Gynecology (FIGO) staging for sarcomas. Descriptive statistics were applied to represent patients characteristics. A retrospective cohort analysis was performed using Kaplan-Meier method to estimate 5-year overall survival (OAS), recurrence free survival (RFS), and cumulative recurrence rates. To compare therapy with or without morcellation log rank test was used. To adjust for age, FIGO stage, grading, rapid growth, abnormal bleeding, and the diagnosis uterus myomatosus, multivariable Cox regression models were applied to estimate hazard ratios (HR). Additionally a forward stepwise variable selection was performed using conditional statistics. All statistical and descriptive analyses were performed using SPSS software version 22.0.
Cancer registration in Bavaria
In Bavaria, the law on the Bavarian Epidemiologic Cancer Registry (Gesetz über das bevölkerungsbezogene Krebsregister Bayern-BayKRG) allows the continuous and uniform data acquisition and processing of cancer incidences by means of an epidemiologic cancer registry [9] . The purpose of this law is to regulate cancer control and to improve data quality of cancer epidemiology. The Bavarian Epidemiologic Cancer Registry has to provide anonymous data for scientific research. Informed consent has to be given in accordance with the Declaration of Helsinki and is an indispensable precondition for data storage. Any physician has to adequately inform the patients about the intended or performed transmission of data to the registry. Patients also receive written information about these procedures. Each patient has the right to object data storage at any time. On the basis of this law, retrospective analyses of anonymous data require no additional ethics statement [9] .
Results
Between January 2008 and December 2013 a total of 984 patients with myomata were treated with hysterectomy at the Department of Gynecology and Obstetrics, University of Regensburg. The proportion of incidental ULMS among the myoma resections in this period was 0.51 % (n = 5).
Two women underwent open abdominal and three patients laparoscopic hysterectomy. In a second step we performed outcome analysis in a smaller subset of 75 patients with histological proven ULMS documented in the clinical cancer registry of the Tumor Center Regensburg between January 2004 and December 2013 in the region of Upper Palatinate and Lower Bavaria (10 years). Due to incomplete follow-up data 11 patients were excluded. Thus, a cohort of 64 patients treated in 16 departments remained for subsequent statistical analyses. The average age at diagnosis was 53.8 years, median age was 52.9 years. Preoperatively three main initial diagnostical parameters could be identified from clinical records: rapid growth of myoma or the uterus (21.9 %, n = 14), uterus myomatosus (54.7 %, n = 35), and abnormal bleeding (42.2 %, n = 27). FIGO stage was distributed as follows: I in 31, II in 13, III in 7, and IV in 10 patients (Table 1 ). In three women staging was not available. All patients (100 %) received primary surgery. 67.2 % (n = 43) of all patients underwent laparotomy, 17.2 % (n = 11) had a laparoscopic approach (LASH and TLH), 9.4 % (n = 6) were performed vaginally and the remaining 6.3 % (n = 4) had a switch from laparoscopic to open abdominal hysterectomy. In 15 women morcellation was used (23.4 %). In 15.6 % (n = 10) radiotherapy, in 14.1 % (n = 9) chemotherapy, and in 6.3 % (n = 6) radio-and chemotherapy was administered as additional treatment. 41 women (64.1 %) did not receive any additional primary therapy. The basic characteristics of patients compared with and without morcellation are summarized in Table 1 . The mean age for morcellation was 50.7 ± 8.5 years (median age 48.7) compared to non-morcellation with 54.7 ± 11.7 years (median age 54.6). In the morcellation group 66.7 % (n = 10) had FIGO stage I and 33.3 % (n = 5) G1 tumors. In the non-morcellation group FIGO stage and grading was higher with only 42.9 % (n = 21) FIGO stage I and 18.4 % (n = 14) G1 tumors. Residual tumor classification was not available in 66.7 % (n = 10) of the patients with morcellation.
Survival analysis
The Kaplan-Meier estimator for median follow-up was 5. 
Discussion
By reviewing literature for incidental ULMS rate in patients with myoma resections the percentages varied from 0.07 [10] to 0.49 [11] . Our percentage of 0.51 is at the upper bound of values reported previously. The rate may be overestimated since our department is also a center for gynecologic oncology. In the cohort of 64 patients 15 patients underwent morcellation. This number is lower than in other studies where up to 45 % of all reviewed patients underwent morcellation [12] . Median OAS for morcellation was 10.6 vs. 6.4 years for non morcellation. 5y-OAS was 76.0 % for morcellation compared to 54.8 % in patients without morcellation. 5y-RFR was 64.0 % compared to 42.8 % in patients without morcellation. These differences in the results were not statistically significant. Better outcomes of patients who were treated by surgery with morcellation could result from earlier stages and better grading of their disease. Morcellation is actually one of the most intensively discussed factors of prognosis in patients with ULMS. Several studies have been published reporting worse outcome after use of intraperitoneal morcellation in primary surgery, most likely due to intra-abdominal spreading of malignant tissue [12] [13] [14] [15] . In a retrospective unicenter analysis including 56 ULMS patients for FIGO stages I and II (44.6 % had morcellation) and a mean follow-up of 52 months Park et al. found a poorer OAS (73 % compared to 46 %) and RFS (65 % compared to 40 %) for patients who underwent morcellation [12] . Similar results were reported by George et al.
Their retrospective unicenter analysis with 58 ULMS patients (32.8 % had morcellation) and a minimum 6 months follow-up demonstrated a poorer RFS (10.8 compared to 39.6 months) and poorer OAS rate at 36 months (64 % compared to 73 %) for patients who underwent morcellation [16] . A systematic review performed by Ebner et al. evaluated 16 articles on the effect of tumor morcellation and surgical techniques showed that at least two-thirds of the cases were early stage ULMS. These findings are consistent with our results where 66.8 % of our ULMS patients had FIGO Stage I and II. Moreover, this systematic literature review found that morcellation in early-stage ULMS was associated with a high probability of peritoneal dissemination and reduced OAS and RFS [17] . There is only one study showing that there is no difference in prognosis between a group with and without morcellation. Morice et al. conducted a retrospective unicenter analysis in 2003 analyzing 123 patients with uterine sarcoma (28 % had morcellation). Recurrence was observed in 87 patients. Non significant rates (p = 0.25) of pelvic recurrence after 3 months were increased in patients who underwent uterine morcellation. After 6 months the rates of pelvic recurrences were not different (10 % compared to 10.4 % for morcellation). Overall and disease-free survival were similar in both groups [15] . The majority (67.2 %) of our patients with presumed uterus myomatosus was treated by laparotomy. Following the results from literature we expected better results for abdominal hysterectomies compared to laparoscopy/morcellation, because of avoided tumor disruption by en bloc resection [15, 16] . In contrast we found that patients who underwent morcellation had a better outcome in OAS and RFS compared to non morcellation, even after adjustment for age, grading, FIGO stage, rapid growth, uterus myomatosus, and abnormal bleeding ( Fig. 1 ; Table 2 ). This advantage in outcome results was not statistically significant. Comparing morcellation and non morcellation groups there are often disparities in clinical factors, e.g., age [16] . Patients in the morcellation cohort are mostly younger at diagnosis, but had a worse outcome. However, Zivanovic, et al., associated younger age with better outcome in ULMS [18] . Adjusting our results for age alone, the group of patients that received morcellation still had a better outcome compared to the non morcellation group as far as survival and risk of recurrences are concerned. Due to the rarity of ULMS the indication of a presumed uterus myomatosus shows no evidence for ULMS diagnosis, but in confirmed diagnosis those women had a better OAS (p = 0.03). Abnormal bleeding was described as the most common preoperative symptom. A recent study performed by Cantú de León in 2013 reported abnormal bleeding in 46.7 % as the most frequent symptom at the time of diagnosis [19] .
Interpreting our results, abnormal bleeding is a decision factor for early surgery, leading to a quick diagnosis. Few studies report about rapid growth [20, 21] . According to the literature rapid growth is no diagnostic tool for discrimination between ULMS and myoma. As confirmed in our study only 21.9 % of the patients having rapid growth as symptom. For rapid growth and abnormal bleeding we observed no significant influence on OAS and RFS. As limitations of this study we have to mention that 10 out of 15 (66.7 %) patients in whom morcellation was performed had FIGO stage I compared to 42.9 % of patients without morcellation. This might be an explanation for better outcomes after morcellation, but only in part which is shown by the results of the multivariable Cox regression analysis. In our evaluation we noticed that there was a high number of undefined gradings (26.6 % Gx and 26.7 % among them had morcellation) and residual tumors (40.6 % Rx and 66.7 % among them had morcellation). We hypothesized that those numbers resulted from the diagnostical dilemma caused by morcellated tumor tissue. Missing pathological determination of depth of myometrial invasion and the inability to evaluate the borders of the lesion and the necrosis are reported in literature [22] [23] [24] . If the better outcomes were real then it could be possible that with respect to embryologically determined compartment association and topical information of tumor cells and hosts immune system at least part of the ULMS are not able to implant on the peritoneal surface. The strengths of our study were that we analysed a relatively high number of patients from 16 gynecological departments in the setting of a population-based clinical cancer registry within the same health care system. Comorbidities were not registered in our database and have consequently not been taken into account, which may have an effect on OAS. Moreover, the number of patients included in this study is still small and therefore results have to be interpreted with caution. In conclusion, we described that morcellation had not the anticipated unfavorable effect as described in most but not all previous studies. However, the number of patients in this study is too small to draw a clear conclusion concerning the risk of morcellation of ULMS. Therefore, it should be avoided at least in patients who show evidence for suspicious pelvic masses. Those who desire laparoscopic techniques that include morcellation have to be informed about the potential risk.
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